[cnbc 3000086926]
Mark Schoenebaum, ISI Group analyst, explains why he thinks Pfizer will modestly beat expectations tomorrow and discusses several new drugs in the company’s pipeline.
Melissa Lee anchors a fast-paced discussion among four professional Wall Street traders. An hour after the bell Fast Money hosts one of the best trading discussions of the day.
Video © and provided by CNBC.
Be the first to comment